GlassScriptPhysician profile
Timothy W Schiller
NPI 1063483618
$5,062.37
in general payments reported to CMS, 2019-2025
32 companies · $329 in 2025
The $329 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,450 · 2020: $1,000 · 2021: $665 · 2022: $680 · 2023: $448 · 2024: $492 · 2025: $329.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,268.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $656.15 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $606.84 | 2019-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $485.60 | 2019-2024 | Farxiga, Breztri |
| Glaxosmithkline, LLC. | $397.39 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $273.23 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amarin Pharma, INC. | $265.25 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $217.82 | 2019-2023 | Belsomra |
| Sanofi-Aventis U.S. LLC | $194.44 | 2020-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $180.70 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $169.75 | 2019-2021 | |
| Pfizer INC. | $157.13 | 2019-2025 | |
| Exact Sciences Corporation | $140.45 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Janssen Pharmaceuticals, INC | $134.20 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $132.12 | 2019-2025 | Zoryve |
| Abbott Laboratories | $131.68 | 2021-2023 | Freestyle Libre 3 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $129.24 | 2021-2025 | Qulipta, Ubrelvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $97.72 | 2020-2023 | Xifaxan |
| Idorsia Pharmaceuticals US INC | $81.00 | 2023-2024 | Quviviq |
| Genentech USA, INC. | $77.64 | 2019-2022 | |
| Astellas Pharma US INC | $77.59 | 2019-2025 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $72.28 | 2022 | |
| Corium, LLC | $67.21 | 2023-2024 | Azstarys |
| Allergan, INC. | $55.48 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $50.05 | 2024 | Voquezna |
| Esperion Therapeutics, INC. | $46.12 | 2020-2023 | Nexletol |
| Dexcom, INC. | $35.03 | 2021-2025 | Dexcom G6 Transmitter |
| Sanofi Pasteur INC. | $32.26 | 2019 | |
| Novartis Pharmaceuticals Corporation | $27.17 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $19.82 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.86 | 2024 | |
| Axsome Therapeutics, INC. | $16.72 | 2025 | Symbravo |
| Dynavax Technologies Corporation | $16.43 | 2025 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Schiller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.